Physician profile
Jerry Mitchell
NPI 1750339651
$27,804.15
in general payments reported to CMS, 2019-2025
35 companies · $62.67 in 2025
The $62.67 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $6,759 · 2021: $1,052 · 2022: $59.92 · 2023: $33.85 · 2024: $39.99 · 2025: $62.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $11,439.41 | 2019 | |
| Sun Pharmaceutical Industries INC. | $5,239.05 | 2019 | |
| Rigel Pharmaceuticals, INC. | $4,144.76 | 2019-2020 | |
| Seagen INC. | $1,774.49 | 2019-2023 | Tukysa |
| Genzyme Corporation | $1,538.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,439.61 | 2019-2020 | |
| Celgene Corporation | $961.03 | 2019-2021 | |
| Eisai INC. | $177.46 | 2019-2022 | |
| Exelixis INC. | $169.49 | 2019-2020 | |
| Amgen INC. | $136.11 | 2019-2020 | |
| Taiho Oncology, INC. | $94.06 | 2020-2021 | |
| Foundation Medicine, INC. | $76.36 | 2020-2023 | Foundationone Liquid Cdx |
| Beigene USA, INC. | $75.76 | 2020-2021 | |
| Abbvie INC. | $62.67 | 2025 | |
| Glaxosmithkline, LLC. | $59.73 | 2020-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $49.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.48 | 2020 | |
| Dendreon Pharmaceuticals LLC | $24.69 | 2020 | |
| Emd Serono, INC. | $24.14 | 2020 | |
| Dova Pharmaceuticals | $23.49 | 2020 | |
| Janssen Biotech, INC. | $23.08 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $21.78 | 2019 | |
| Innate Pharma, INC | $19.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.48 | 2020 | |
| Acceleron Pharma, INC. | $16.27 | 2020 | |
| Agios Pharmaceuticals, INC. | $15.98 | 2020 | |
| Secura Bio, INC. | $14.81 | 2020 | |
| Pfizer INC. | $13.92 | 2019 | |
| Blueprint Medicines Corporation | $13.82 | 2020 | |
| Coherus Oncology, INC. | $13.45 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.87 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.77 | 2019 | |
| Aurobindo Pharma USA, INC. | $12.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.